Shots:
- Debiopharm has entered into an exclusive global licensing agreement with Repare Therapeutics for lunresertib (PKMYT1 inhibitor) to treat difficult-to-treat solid tumors
- As per the deal, Repare will receive $10M upfront, ~$257M in clinical, regulatory, commercial & sales milestones, incl. $5M in near-term payments & net sales-based single-digit royalties
- Debiopharm will assume sponsorship of P-I (MYTHIC) trial assessing lunresertib + Debio 0123 under Repare & Debiopharm’s Jan 2024 partnership; Debiopharm will also take over responsibility of all lunresertib-related development activities
Ref: Businesswire | Image: Debiopharm| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
